INVEGA HAFYERA^® extrapyramidal symptoms evaluated across studies

EPS=extrapyramidal symptoms.

*Use of anti-EPS medication during the double-blind phase.

^†Percentage of patients with Simpson-Angus Scale Global Score >0.3 (Global Score defined as the total sum of items score divided by the number of items).

^‡Percentage of patients with Barnes Akathisia Rating Scale Global Clinical Rating Score ≥2.

^§Percentage of patients with a score ≥3 on any of the first 7 items or a score ≥2 on 2 or more of any of the first 7 items of the Abnormal Involuntary Movement Scale.

Note: Percentages are calculated based on the number of patients in the double-blind safety analysis set per treatment group.